PHARMACYTE BIOTECH INC (PMCB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.49-0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve positive free cash flow: FCF yield -0.6% vs 0% target.
PharmaCyte Biotech is advancing cell therapies for cancer and diabetes. The company completed an acquisition in September 2025, which could boost its pipeline. Despite a market drawdown of 25.2%, it remains listed on Nasdaq. The company aims to recover from losses and build value.
PharmaCyte is loss-making with negative free cash flow yield of -0.73. It faced a Nasdaq delisting notice in December 2025. The stock has fallen 25% from its high and recent private placements dilute shareholders. The turnaround may stall or fail to generate revenue growth.
The market is selling off the stock with a 25% drawdown reflecting high risk and uncertainty. No consensus revenue or earnings growth is priced in, consistent with the company’s unprofitable status and lack of guidance. Our view is cautious given the weak fundamentals and regulatory risks.
Breaks if: Free cash flow yield remains negative beyond next 4 quarters
Breaks if: No meaningful clinical progress or regulatory setbacks occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious, as recent financial performance has been weak, but there is potential for improvement if sector trends remain favorable.
The market appears to be pricing in a high level of risk, given PMCB's loss-making status and fragile earnings quality. Expectations may be low due to recent misses, which could create an expectations gap if performance improves.
Management stability is a positive sign, but the recent financial performance has been weak. There is an elevated risk of a next-quarter earnings miss, which could further impact investor sentiment.
The future trajectory hinges on macroeconomic factors, particularly job reports, and the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive momentum in these companies could support PMCB, while negative trends could pose significant challenges.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Any new Nasdaq delisting notice or trading suspension issued
Overall, PMCB's outlook remains uncertain with a mix of risks and potential opportunities. Not investment advice.